<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00128921</url>
  </required_header>
  <id_info>
    <org_study_id>UARK 2004-22</org_study_id>
    <nct_id>NCT00128921</nct_id>
  </id_info>
  <brief_title>Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma</brief_title>
  <official_title>A Phase II Dose-Response Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Velcade (bortezomib, PS-341) has recently been approved by the Food and Drug Administration&#xD;
      (FDA) for the treatment of multiple myeloma for patients who have received at least one prior&#xD;
      therapy. Velcade is a unique compound developed by scientists at Millennium Pharmaceuticals,&#xD;
      Inc. Velcade enters cells and affects the way they divide. Cancer cells are particularly&#xD;
      sensitive. Velcade interferes with the enzyme &quot;proteasome&quot; which is responsible for allowing&#xD;
      cells to divide. When cancer cells cannot divide, they die. Velcade falls into the class of&#xD;
      drugs known as &quot;proteasome inhibitors.&quot;&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies at the Myeloma Institute for Research &amp; Therapy have shown that Velcade is very&#xD;
      effective in treating patients who are relapsing after having been treated with at least two&#xD;
      lines of prior therapy.&#xD;
&#xD;
      One key factor in multiple myeloma is bone destruction caused by the myeloma cells. Most&#xD;
      patients with multiple myeloma (80%) will develop skeletal lesions, despite treatment. These&#xD;
      lesions are rarely repaired, even when the myeloma is in remission.&#xD;
&#xD;
      Experience at MIRT has suggested that Velcade may increase osteoblast (bone cells that cause&#xD;
      bone growth) activity. One goal of this study is to identify if Velcade's effect on myeloma&#xD;
      is due to its ability to increase osteoblasts.&#xD;
&#xD;
      This study also has the following goals:&#xD;
&#xD;
        -  To find out the lowest dose of Velcade that has an effect on myeloma and also increases&#xD;
           bone activation;&#xD;
&#xD;
        -  To identify ways to predict if Velcade will increase bone activation.&#xD;
&#xD;
      Time periods are:&#xD;
&#xD;
      According to cohort assignment, you will receive three cycles of Velcade®™ (1.3 mg/m2, 1.0&#xD;
      mg/m2 or 0.7 mg/m2) on days 1, 4, 8, and 11, on a 21-day cycle.&#xD;
&#xD;
      During the first two cycles of Velcade®™, bone markers (tests on your bones) will be measured&#xD;
      Days 1, 4, 8, 11: Pre-dose, post-dose, and every 2 to 4 hours for 8 hours.&#xD;
&#xD;
      Days 2-3, 5-7, 9-10, 12-21: every 24 hours, beginning with the immediate post-dose sample&#xD;
      (+/- 2 hours)&#xD;
&#xD;
      During the third cycle of Velcade®™, bone markers will be measured Days 1 and 11: Pre-dose&#xD;
      and post-dose, and then again on Day 21.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    study terminated due to low accrual&#xD;
  </why_stopped>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Positive Response to Bortezomib Measured by the Bone Marker Parathyroid Hormone</measure>
    <time_frame>6 months</time_frame>
    <description>Parathyroid hormone: Any increase in PTH was considered response</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With a Positive Response to Bortezomib Measured by Bone Markers Like Calcium</measure>
    <time_frame>6 months</time_frame>
    <description>Calcium: any Calcium increase would refer to a positive response.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With a Positive Response to Bortezomib Measured by Bone Marker Alkaline Phosphatase</measure>
    <time_frame>6 months</time_frame>
    <description>Alkaline phosphatase: If the Alkaline phosphatase increases it's considered positive response</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With a Positive Response to Bortezomib Measured by Bone Markers Like Magnesium</measure>
    <time_frame>6 months</time_frame>
    <description>Magnesium: Any Magnesium increase would refer to a positive response.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With a Positive Response to Bortezomib Measured by Bone Markers Like Phosphate.</measure>
    <time_frame>6 months</time_frame>
    <description>Phosphate: any Phosphate increase would refer to a positive response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Positive Response to Bortezomib Measured by Bone Marker Osteocalcin</measure>
    <time_frame>6 months</time_frame>
    <description>Osteocalcin: Any Osteocalcin increase means positive response.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Velcade, Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment: 1.3 mg/m^2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Velcade, Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment: 1.0 mg/m^2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Velcade, Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment: 0.7 mg/m^2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VELCADE™</intervention_name>
    <description>Patients will receive two cycles of VELCADE™ (1.3 mg/m2, 1.0 mg/m2 or 0.7 mg/m2) on days 1, 4, 8, and 11, on a 21 day cycle. No growth factors or bisphosphonates will be allowed during study treatment. Bone markers will be measured:&#xD;
Days 1, 4, 8, 11: Pre-dose, post-dose, and every 2-4 hours for 8 hours Days 2-3, 5-7, 9-10, 12-21: every 24 hours, beginning with the immediate post-dose sample (+/- 2 hours) Other laboratory and radiologic studies will be performed as detailed in the Study Calendar.&#xD;
Patients will complete the study after two cycles of VELCADE™. However, if a patient continues to receive VELCADE™ as part of his/her treatment for relapsing MM, routine bone markers may be monitored for the duration of VELCADE™ treatment as clinically indicated.</description>
    <arm_group_label>Velcade, Cohort A</arm_group_label>
    <arm_group_label>Velcade, Cohort B</arm_group_label>
    <arm_group_label>Velcade, Cohort C</arm_group_label>
    <other_name>Bortezomib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  History of histologically documented MM with relapsed or progressive disease after at&#xD;
             least one line of prior therapy.&#xD;
&#xD;
          -  Patient has measurable disease in which to capture response, defined as one or more of&#xD;
             the following:&#xD;
&#xD;
               -  Serum M-protein level &gt; 1.0 gm/dl (10.0 g/L) measured by serum protein&#xD;
                  electrophoresis or immunoglobulin electrophoresis; or&#xD;
&#xD;
               -  Urinary M-protein excretion &gt; 1000 mg/24 hours; or&#xD;
&#xD;
               -  Bone marrow plasmacytosis of &gt; 30% by bone marrow aspirate and/or biopsy; or&#xD;
&#xD;
               -  Serum free light chains (by the Freelite test) &gt; 2 X the upper limit of normal,&#xD;
                  in the absence of renal failure.&#xD;
&#xD;
               -  Evidence of active disease by radiographic techniques&#xD;
&#xD;
          -  Performance status (PS) of &lt;= 2 as per Southwest Oncology Group scale, unless PS of&#xD;
             3-4 based solely on bone pain.&#xD;
&#xD;
          -  Patients must have a platelet count &gt;= 50,000/mm3, and an absolute neutrophil count of&#xD;
             at least 1,000/μl.&#xD;
&#xD;
          -  Patients must have adequate renal function defined as creatinine clearance &gt; 30ml/min.&#xD;
&#xD;
          -  Patients must have adequate hepatic function defined as serum transaminases and direct&#xD;
             bilirubin &lt; 2 X the upper limit of normal.&#xD;
&#xD;
          -  Pregnant or nursing women may not participate. Women of childbearing potential must&#xD;
             have a negative pregnancy test documented within one week of registration. Women of&#xD;
             reproductive potential may not participate unless they have agreed to use an effective&#xD;
             contraceptive method.&#xD;
&#xD;
          -  Male or female adults of at least 18 years of age.&#xD;
&#xD;
          -  Patients must have signed and Institutional Review Board approved written informed&#xD;
             consent form and demonstrate willingness to meet follow-up schedule and study&#xD;
             procedure obligations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chemotherapy or radiotherapy received within the previous 4 weeks.&#xD;
&#xD;
          -  Has received previous bortezomib therapy&#xD;
&#xD;
          -  Significant neurotoxicity, defined as grade &gt; 2 neurotoxicity per National Cancer&#xD;
             Institute Common Toxicity Criteria.&#xD;
&#xD;
          -  Platelet count &lt; 50,000/mm3, or ANC &lt; 1,000/μl&#xD;
&#xD;
          -  Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes&#xD;
             syndrome.&#xD;
&#xD;
          -  Patient has hypersensitivity to bortezomib, boron, or mannitol&#xD;
&#xD;
          -  Clinically significant hepatic dysfunction as noted by bilirubin or AST &gt;3 times the&#xD;
             upper normal limit or clinically significant concurrent hepatitis.&#xD;
&#xD;
          -  New York Hospital Association Class III or Class IV heart failure.&#xD;
&#xD;
          -  Myocardial infarction within the last 6 months.&#xD;
&#xD;
          -  Non-secretory multiple myeloma, unless the patient has measurable lesions on computed&#xD;
             tomography, magnetic resonance imaging and/or positron emission tomography.&#xD;
&#xD;
          -  Uncontrolled, active infection.&#xD;
&#xD;
          -  Patients with a history of treatment for clinically significant ventricular cardiac&#xD;
             arrhythmias.&#xD;
&#xD;
          -  Poorly controlled hypertension, diabetes mellitus, or other serious or psychiatric&#xD;
             illness that could potentially interfere with the completion of treatment according to&#xD;
             this protocol.&#xD;
&#xD;
          -  Pregnant or potential for pregnancy. Women of childbearing potential will have a&#xD;
             pregnancy [beta-HCG] test at screening, and will be required to use a medically&#xD;
             approved contraceptive method. Pregnancy testing will be performed prior to&#xD;
             administration of each cycle of study drug.&#xD;
&#xD;
          -  Breast-feeding women may not participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maurizio Zangari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>August 8, 2005</study_first_submitted>
  <study_first_submitted_qc>August 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2005</study_first_posted>
  <results_first_submitted>April 15, 2011</results_first_submitted>
  <results_first_submitted_qc>April 25, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 26, 2012</results_first_posted>
  <last_update_submitted>April 25, 2012</last_update_submitted>
  <last_update_submitted_qc>April 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment was between 4/17/2006 to 11/26/2007. The Recruitment occurred in the Myeloma outpatient clinic.</recruitment_details>
      <pre_assignment_details>Enrollment plan was as follows: The first 10 were enrolled in Arm A, the next 10 were enrolled in Arm B and the last 10 were to be enrolled in Arm C. 10 participants were enrolled on Arm A, 8 participants on Arm B and 0 on Arm C. Of the 8 participants in Arm B, only 6 were analyzed because 2 withdrew before receiving bortezomib.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Bortezomib, Cohort a</title>
          <description>treatment: 1.3 mg/m^2</description>
        </group>
        <group group_id="P2">
          <title>Bortezomib, Cohort b</title>
          <description>treatment: 1.0 mg/m^2</description>
        </group>
        <group group_id="P3">
          <title>Bortezomib, Cohort c</title>
          <description>treatment: 0.7 mg/m^2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Bortezomib</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bortezomib, Cohort a</title>
          <description>treatment: 1.3 mg/m^2</description>
        </group>
        <group group_id="B2">
          <title>Bortezomib, Cohort b</title>
          <description>treatment: 1.0 mg/m^2</description>
        </group>
        <group group_id="B3">
          <title>Bortezomib, Cohort c</title>
          <description>treatment: 0.7 mg/m^2</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="8.78"/>
                    <measurement group_id="B2" value="70.75" spread="8.69"/>
                    <measurement group_id="B4" value="67.55" spread="8.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Positive Response to Bortezomib Measured by the Bone Marker Parathyroid Hormone</title>
        <description>Parathyroid hormone: Any increase in PTH was considered response</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Cohort A: Parathyroid hormone (participants received bortezomib 1.3 mg/m2 per days 1, 4, 8 and 11 for three 21-day cycles)</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>Cohort B: Parathyroid hormone (participants received bortezomib 1.0 mg/m2 per days 1, 4, 8 and 11 for three 21-day cycles)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Positive Response to Bortezomib Measured by the Bone Marker Parathyroid Hormone</title>
          <description>Parathyroid hormone: Any increase in PTH was considered response</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Positive Response to Bortezomib Measured by Bone Markers Like Calcium</title>
        <description>Calcium: any Calcium increase would refer to a positive response.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Cohort A: Received bortezomib 1.3 mg/m2 per days 1, 4, 8 and 11.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>Cohort B: Received bortezomib 1.0 mg/m2 per days 1, 4, 8 and 11.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Positive Response to Bortezomib Measured by Bone Markers Like Calcium</title>
          <description>Calcium: any Calcium increase would refer to a positive response.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Positive Response to Bortezomib Measured by Bone Marker Osteocalcin</title>
        <description>Osteocalcin: Any Osteocalcin increase means positive response.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Cohort A: Received bortezomib 1.3 mg/m2 per days 1, 4, 8 and 11.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>Cohort B: Received bortezomib 1.0 mg/m2 per days 1, 4, 8 and 11).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Positive Response to Bortezomib Measured by Bone Marker Osteocalcin</title>
          <description>Osteocalcin: Any Osteocalcin increase means positive response.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Positive Response to Bortezomib Measured by Bone Marker Alkaline Phosphatase</title>
        <description>Alkaline phosphatase: If the Alkaline phosphatase increases it's considered positive response</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Cohort A: Received bortezomib 1.3 mg/m2 per days 1, 4, 8 and 11.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>Cohort B: Received bortezomib 1.0 mg/m2 per days 1, 4, 8 and 11.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Positive Response to Bortezomib Measured by Bone Marker Alkaline Phosphatase</title>
          <description>Alkaline phosphatase: If the Alkaline phosphatase increases it's considered positive response</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4.5" upper_limit="48.4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Positive Response to Bortezomib Measured by Bone Markers Like Magnesium</title>
        <description>Magnesium: Any Magnesium increase would refer to a positive response.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Cohort A: Received bortezomib 1.3 mg/m2 per days 1, 4, 8 and 11.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>Cohort B: Received bortezomib 1.0 mg/m2 per days 1, 4, 8 and 11.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Positive Response to Bortezomib Measured by Bone Markers Like Magnesium</title>
          <description>Magnesium: Any Magnesium increase would refer to a positive response.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Positive Response to Bortezomib Measured by Bone Markers Like Phosphate.</title>
        <description>Phosphate: any Phosphate increase would refer to a positive response.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Cohort A: Received bortezomib 1.3 mg/m2 per days 1, 4, 8 and 11.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>Cohort B: Received bortezomib 1.0 mg/m2 per days 1, 4, 8 and 11.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Positive Response to Bortezomib Measured by Bone Markers Like Phosphate.</title>
          <description>Phosphate: any Phosphate increase would refer to a positive response.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The adverse event data was collected for a period of 1 year and 9 months, between 4/17/2006 to 12/26/2007</time_frame>
      <desc>Adverse event data for cohort b was collected only for 6 participants, as 8 participants were enrolled but 2 did not start the protocol step</desc>
      <group_list>
        <group group_id="E1">
          <title>Bortezomib, Cohort a</title>
          <description>treatment: 1.3 mg/m^2</description>
        </group>
        <group group_id="E2">
          <title>Bortezomib, Cohort b</title>
          <description>treatment: 1.0 mg/m^2</description>
        </group>
        <group group_id="E3">
          <title>Bortezomib, Cohort c</title>
          <description>treatment: 0.7 mg/m^2</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>unsteady gait and mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to difficulty in accruing participants.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Nathan M. Petty</name_or_title>
      <organization>University of Arkansas for Medical Sciences, Myeloma Institute</organization>
      <phone>501-526-6990 ext 2461</phone>
      <email>pettynathanm@uams.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

